How to Buy Crescent Biopharma, Inc. Common Stock (CBIO) Stock

Where to buy CBIO

13 brokers in our matrix offer CBIO. Verify availability and current fees with each broker before trading.

Broker	Commission	Fractional	Extended	Overnight	Options	OTC access
Charles Schwab (thinkorswim)Review	$0	Schwab Stock Slices, S&P 500 only, ≥ $5/slice, up to 30 at once		~1,130	$0.65	Most (3/5)
E*TRADE (Morgan Stanley)Review	$0 listed			~20	$0.65	Most (4/5)
FidelityReview	$0	Stocks by the Slice, 7,000+ stocks/ETFs, from $1			$0.65	Partial (2+0)
FirstradeReview	$0	~4,000+ tickers, ≥ $5		~1,200	$0	Most (4/5)
Interactive BrokersReview	$0 (Lite) / per-share (Pro)			~10,000	per-contract pricing	Full
Merrill EdgeReview	$0				$0.65	Most (3/5)
MoomooReview	$0				$0	Limited only
Public.comReview	$0				rebate model	Limited only
RobinhoodReview	$0	≥ $1 stocks, market cap ≥ $25M		~1,134	$0	None
SoFi Active InvestingReview	$0				$0	Partial (1+2)
tastytradeReview	$0 stocks				$1.00 open, $0 close (capped at $10 per leg)	Limited only
TradeStationReview	$0 listed				$0.50 / $0.60	Most (4/5)
WebullReview	$0				$0	Limited only

24-Hour / Overnight trading

CBIO may be eligible for overnight trading via Charles Schwab (thinkorswim), Interactive Brokers, Robinhood, E*TRADE (Morgan Stanley), Webull, Moomoo, Firstrade. Each broker maintains its own eligibility list — confirm before placing an order.

About Crescent Biopharma, Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Sector

PHARMACEUTICAL PREPARATIONS

Employees

44

Headquarters

WALTHAM, MA

Listed

2025-06-16

Market cap

$521.44M

Frequently asked

Where can I buy Crescent Biopharma, Inc. Common Stock (CBIO)?

CBIO is offered by 13 brokers in our matrix, including Charles Schwab (thinkorswim), E*TRADE (Morgan Stanley), Fidelity, Firstrade, Interactive Brokers. Compare commissions, fractional eligibility, and overnight availability in the broker matrix above.

Can I buy CBIO after hours or overnight?

Yes. CBIO is on the 24-hour eligibility list for Charles Schwab (thinkorswim), Interactive Brokers, Robinhood, E*TRADE (Morgan Stanley), and others. Overnight sessions route through ATSs with wider spreads and limit-orders only.

Does Robinhood offer CBIO?

Yes. Robinhood offers CBIO as a regular exchange-listed security.

Does Fidelity offer CBIO?

Yes. Fidelity offers CBIO as a regular exchange-listed security.

Does Webull offer CBIO?

Yes. Webull offers CBIO as a regular exchange-listed security.

Is CBIO optionable?

No. CBIO does not have listed options contracts at the moment.

Is there a tokenized version of CBIO?

Not in our current dataset. The tokenized stock universe (Kraken xStocks, Binance Alpha/Ondo, Robinhood EU, Hyperliquid HIP-3) is expanding quickly — we refresh quarterly.

Can I buy a fractional share of CBIO?

Yes. Multiple brokers in the matrix support fractional shares for CBIO — see the Fractional column above for per-broker eligibility and minimums.